Beur schreef op 16 maart 2017 12:06:
[...]
"As announced in November 2011, the United States Patent and Trademark Office (USPTO) granted the Company US Patent 8,071,532, covering a method of preventing, reducing or treating IRI by administering Ruconest®. The broad claims in the patent provide protection until 2028. This is Pharming’s first patent granted on IRI in the US, and represents a significant milestone in the continuing development of Ruconest in additional indications associated with IRI such as Delayed Graft Function (DGF) after transplantation. DGF occurs when a lack of oxygen during transplant causes a delayed functioning of the transplanted organ, improper functioning in the longer term and, eventually, in the rejection of the transplanted organ.
As result of the pre-clinical results to date and the granting of the patent, we are evaluating the use of Ruconest® in IRI related indications, including DGF and Acute Myocardial Infarction (AMI). Those indications are commercially attractive markets that are associated with high unmet medical need.
Lack of financial resources during 2012 precluded any other activities other than the already initiated pre-clinical activities for these indications